Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05366218
Title Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia (Anti-CD19-ALL)
Acronym Anti-CD19-ALL
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University Hospital Tuebingen
Age Groups: adult | child
Covered Countries DEU

No variant requirements are available.